briantlord
Brian Lord (SEMA Lab) shares academic analyses and primary-source summaries at the intersection of mindfulness, non-invasive neuromodulation, and neurotech safety. Content emphasizes early-stage studies, methodological detail, and regulatory/reputational risk sensitivity rather than commercial product promotion.
Past bets that played out
Highlights include a placebo-controlled tFUS meditation preprint reporting Default Mode Network connectivity changes and a Biological Psychiatry paper proposing a theoretical framework for combining mindfulness with non-invasive brain stimulation to "enhance equanimity." Both items are academic and conceptual with no near-term commercialization or public-company tie-ins identified.
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
What this channel is watching now
Active topics: transcranial focused ultrasound (tFUS) in meditation training; frameworks for pairing mindfulness with neuromodulation; safety and testing practices for AI/health/neurotech actors. Top tickers mentioned in recent content: STIM, BWAY, LIVN, ECOR, ABT, MDT, NPCE.
Latest videos and market context
No video content provided; recent posts are academic paper announcements and social-media discussion threads about technical transparency and safety.
Brian Lord @briantlord Jan 13, 2025 In case you missed it during the holiday, we at SEMA Lab just published a paper i...
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
Pinned Brian Lord @briantlord Mar 17 🚨 New preprint from SEMA Lab! 🚨 We applied our tFUS meditation enhancement proto...
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
@weslouisberry @PropheticAI That is fantastic to hear. Do/will you have all of that technical information published s...
The content is a social-media reply asking PropheticAI (and a user) whether technical information will be published. It contains no market, macro, company fundamentals, product launch, or financial guidance details that would support a tradable thesis.
@PropheticAI This looks cool, but I *really* hope you are doing proper safety testing, for the sake of the entire fie...
A social post expressing concern about whether PropheticAI is doing proper safety testing; signals reputational/regulatory risk sensitivity around AI/health/neurotech, but contains no concrete claims, data, timelines, product details, or market-moving information.
Proof-backed call history
Recent output is primarily academic preprints and journal highlights from SEMA Lab, plus social posts questioning safety/testing practices in neurotech and AI-assisted health tools. The work is research-first and not positioned as financial advice or commercial product marketing.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
About this channel
Brian Lord (@briantlord) publishes research and commentary through SEMA Lab with a focus on meditation-enhancement protocols, non-invasive brain stimulation methods (including tFUS), and the safety and translational challenges around emerging neurotechnologies. Posts summarize academic findings and raise questions about reproducibility, safety testing, and regulatory considerations.
@briantlord
Most recognized assets
Unlock the full track record
Follow @briantlord for primary-source summaries and methodological commentary on neurotech research. Content is academic and investigational; consult regulatory or clinical sources for product or investment decisions.